<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01183169</url>
  </required_header>
  <id_info>
    <org_study_id>CDEB025A2210</org_study_id>
    <secondary_id>2010-020033-14</secondary_id>
    <nct_id>NCT01183169</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Study on Efficacy and Safety of DEB025 Combined With Peg-IFN Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Relapsers and Non-responders to Previous Peg-IFN Alfa-2 Plus Ribavirin Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Debiopharm International SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Debiopharm International SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to investigate whether participants with hepatitis C virus (HCV) genotype 1 who
      have a history of non-response/relapse to peginterferon alfa-2a (PEG) and ribavirin (RBV) may
      benefit from treatment with triple therapy alisporivir (ALV; DEB025) with PEG and RBV versus
      placebo with PEG and RBV.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Complete Early Viral Response Below the Limit of Quantification (cEVR-LOQ)</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
    <description>cEVR-LOQ was defined as serum HCV RNA below the limit of quantification (&lt; LOQ; i.e., 25 IU/mL) after 12 weeks of treatment. Post-switch groups were assessed 12 weeks after the switch.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Complete Early Viral Response Below the Limit of Detection (cEVR-LOD)</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
    <description>cEVR-LOD was defined as serum HCV RNA below the limit of detection (&lt; LOD; i.e., 10 IU/mL) after 12 weeks of treatment. Post-switch groups were assessed 12 weeks after the switch.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Sustained Viral Response 12 Weeks After Treatment (SVR12)-LOQ and SVR12-LOD</measure>
    <time_frame>12 weeks after treatment</time_frame>
    <description>SVR12-LOQ and SVR12-LOD were defined as serum HCV RNA &lt; LOQ and serum HCV RNA &lt; LOD 12 weeks after treatment, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Sustained Viral Response 24 Weeks After Treatment (SVR24)-LOQ and SVR24-LOD</measure>
    <time_frame>24 weeks after treatment</time_frame>
    <description>SVR24-LOQ and SVR24-LOD were defined as serum HCV RNA &lt; LOQ and serum HCV RNA &lt; LOD 24 weeks after treatment, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Rapid Viral Response (RVR)-LOQ and RVR-LOD</measure>
    <time_frame>after 4 weeks of treatment</time_frame>
    <description>RVR-LOQ and RVR-LOD were defined as serum HCV RNA &lt; LOQ and serum HCV RNA &lt; LOD after 4 weeks of treatment, respectively. Post-switch groups were assessed 4 weeks after the switch.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Partial Early Virologic Response After 12 Weeks of Treatment (pEVR)-LOQ and pEVR-LOD</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
    <description>pEVR-LOQ and pEVR-LOD were defined as a ≥ 2 log10 decrease in HCV RNA and still detectable (≥ LOQ and ≥ LOD, respectively) after 12 weeks of treatment. Post-switch groups were assessed 12 weeks after the switch.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With End of Treatment Response (ETR)-LOQ and ETR-LOD</measure>
    <time_frame>within 48 weeks</time_frame>
    <description>ETR-LOQ and ETR-LOD were defined as serum HCV RNA &lt; LOQ and serum HCV RNA &lt; LOD at treatment end (completed or prematurely discontinued), respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Abnormal Alanine Aminotransferase (ALT) at Baseline Who Had Normalized ALT at Treatment End and Study End</measure>
    <time_frame>Up to 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With On-treatment Viral Breakthrough</measure>
    <time_frame>within 48 weeks</time_frame>
    <description>On-treatment viral breakthrough was defined as either:
Confirmed increase of HCV RNA ≥1 log10 above nadir (nadir = lowest HCV RNA value during treatment), or
HCV RNA becoming ≥ 100 IU/mL after previously being undetectable (&lt; LOQ) during treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Viral Relapse</measure>
    <time_frame>within 24 weeks after treatment</time_frame>
    <description>Viral relapse was defined as reappearance of detectable HCV RNA after previously being undetectable (&lt; LOQ) during treatment.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">459</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Treatment A: ALV 600 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alisporivir (ALV) 600 mg once daily (QD) with Peginterferon alfa-2a (PEG) and Ribavirin (RBV) for up to 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: ALV 800 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alisporivir (ALV) 800 mg QD with PEG and RBV for up to 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C1: ALV Placebo - 600 mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALV Placebo with PEG and RBV for up to 48 weeks; participants not achieving complete early virologic response (cEVR) after 12 weeks of treatment may switch to active ALV 600 mg QD with PEG and RBV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C2: ALV Placebo - 400 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALV Placebo with PEG and RBV for up to 48 weeks; participants not achieving cEVR after 12 weeks of treatment may switch to active ALV 400 mg twice daily (BID) with PEG and RBV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D: ALV 400 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alisporivir (ALV) 400 mg twice daily BID with PEG and RBV for up to 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alisporivir</intervention_name>
    <description>ALV 200 mg soft gel capsules administered orally</description>
    <arm_group_label>Treatment A: ALV 600 mg QD</arm_group_label>
    <arm_group_label>Treatment B: ALV 800 mg QD</arm_group_label>
    <arm_group_label>Treatment C1: ALV Placebo - 600 mg QD</arm_group_label>
    <arm_group_label>Treatment C2: ALV Placebo - 400 mg BID</arm_group_label>
    <arm_group_label>Treatment D: ALV 400 mg BID</arm_group_label>
    <other_name>DEB025</other_name>
    <other_name>ALV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>PEG 180 μg administered via subcutaneous (s.c.) injection once weekly</description>
    <arm_group_label>Treatment A: ALV 600 mg QD</arm_group_label>
    <arm_group_label>Treatment B: ALV 800 mg QD</arm_group_label>
    <arm_group_label>Treatment C1: ALV Placebo - 600 mg QD</arm_group_label>
    <arm_group_label>Treatment C2: ALV Placebo - 400 mg BID</arm_group_label>
    <arm_group_label>Treatment D: ALV 400 mg BID</arm_group_label>
    <other_name>Pegasys®</other_name>
    <other_name>PEG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>RBV 200 mg tablets (weight-based dose: &lt; 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose</description>
    <arm_group_label>Treatment A: ALV 600 mg QD</arm_group_label>
    <arm_group_label>Treatment B: ALV 800 mg QD</arm_group_label>
    <arm_group_label>Treatment C1: ALV Placebo - 600 mg QD</arm_group_label>
    <arm_group_label>Treatment C2: ALV Placebo - 400 mg BID</arm_group_label>
    <arm_group_label>Treatment D: ALV 400 mg BID</arm_group_label>
    <other_name>Copegus®</other_name>
    <other_name>RBV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>ALV placebo soft gel capsules administered orally</description>
    <arm_group_label>Treatment C1: ALV Placebo - 600 mg QD</arm_group_label>
    <arm_group_label>Treatment C2: ALV Placebo - 400 mg BID</arm_group_label>
    <other_name>ALV Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Chronic HCV genotype 1 viral infection

          -  HCV RNA ≥ 1,000 IU/ml assessed by quantitative polymerase chain reaction (qPCR) or
             equivalent at screening

          -  Previous non-responders/relapsers to PEG and RBV after treatment for at least 12 weeks

        Exclusion criteria:

          -  Treatment with any anti-HCV drug (whether approved or investigational) within 3 months
             prior to screening

          -  Women of child-bearing potential unless using highly effective

          -  Any other cause of relevant liver disease other than HCV

          -  Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Egg Harbor Twp</city>
        <state>New Jersey</state>
        <zip>08234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246-2096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <zip>2747</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nice Cedex 3</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75006</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10969</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bekescsaba</city>
        <zip>H-5600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1126</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaposvár</city>
        <zip>7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Antella - Bagno a Ripoli</city>
        <state>FI</state>
        <zip>50012</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-540</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lódz</city>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-201</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Juan</city>
        <zip>00909</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucharest</city>
        <state>District 1</state>
        <zip>050526</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucharest</city>
        <state>District 3</state>
        <zip>030317</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucharest</city>
        <zip>020125</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucharest</city>
        <zip>021105</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Iasi</city>
        <zip>700506</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28029</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <state>Taiwan, ROC</state>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Keelung City</city>
        <zip>20401</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lin-Ko</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Niaosong Township</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yun-Lin</city>
        <zip>640</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06800</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fatih / Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>NW3 2PR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2010</study_first_submitted>
  <study_first_submitted_qc>August 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2010</study_first_posted>
  <results_first_submitted>July 14, 2016</results_first_submitted>
  <results_first_submitted_qc>July 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 25, 2016</results_first_posted>
  <last_update_submitted>July 14, 2016</last_update_submitted>
  <last_update_submitted_qc>July 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic hepatitis C</keyword>
  <keyword>Cyclophilin inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment A</title>
          <description>Alisporivir (ALV; DEB025) 600 mg once daily (QD) with peginterferon alfa-2a (PEG) and ribavirin (RBV) for up to 48 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Treatment B</title>
          <description>ALV 800 mg QD with PEG and RBV for up to 48 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Treatment C1</title>
          <description>Treatment C subset C1: ALV placebo with PEG and RBV for up to 48 weeks; participants not achieving complete early virologic response (cEVR: hepatitis C virus (HCV) ribonucleic acid (RNA) &lt;LOQ after 12 weeks of treatment) could switch to active ALV 600 mg QD with PEG and RBV.</description>
        </group>
        <group group_id="P4">
          <title>Treatment C2</title>
          <description>Treatment C subset C2: ALV placebo with PEG and RBV for up to 48 weeks; participants not achieving cEVR could switch to active ALV 400 mg twice daily (BID) with PEG and RBV.</description>
        </group>
        <group group_id="P5">
          <title>Treatment D</title>
          <description>ALV 400 mg BID with PEG and RBV for up to 48 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Treatment C1A</title>
          <description>ALV 600 mg QD with PEG and RBV in participants not achieving cEVR in Treatment C subset C1.</description>
        </group>
        <group group_id="P7">
          <title>Treatment C2A</title>
          <description>ALV 400 mg BID with PEG and RBV in participants not achieving cEVR in Treatment C subset C2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Main Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="59"/>
                <participants group_id="P4" count="55"/>
                <participants group_id="P5" count="109"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="17"/>
                <participants group_id="P5" count="77"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Switched to ALV</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="93"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="18"/>
                <participants group_id="P5" count="83"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="37"/>
                <participants group_id="P5" count="26"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Post-switch Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Not a post-switch group</participants>
                <participants group_id="P2" count="0">Not a post-switch group</participants>
                <participants group_id="P3" count="0">Not a post-switch group</participants>
                <participants group_id="P4" count="0">Not a post-switch group</participants>
                <participants group_id="P5" count="0">Not a post-switch group</participants>
                <participants group_id="P6" count="35">Participants in Treatment C1 who switched to active ALV</participants>
                <participants group_id="P7" count="30">Participants in Treatment C2 who switched to active ALV</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="21"/>
                <participants group_id="P7" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="14"/>
                <participants group_id="P7" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>Treatment A</title>
          <description>ALV 600 mg QD with PEG and RBV for up to 48 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Treatment B</title>
          <description>ALV 800 mg QD with PEG and RBV for up to 48 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Treatment C</title>
          <description>Treatment C1 + Treatment C2. ALV placebo with PEG and RBV for up to 48 weeks; participants not achieving cEVR could switch to active ALV.</description>
        </group>
        <group group_id="B4">
          <title>Treatment D</title>
          <description>ALV 400 mg BID with PEG and RBV for up to 48 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="121"/>
            <count group_id="B2" value="115"/>
            <count group_id="B3" value="114"/>
            <count group_id="B4" value="109"/>
            <count group_id="B5" value="459"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.2" spread="9.24"/>
                    <measurement group_id="B2" value="50.9" spread="10.11"/>
                    <measurement group_id="B3" value="50.5" spread="10.50"/>
                    <measurement group_id="B4" value="51.0" spread="9.68"/>
                    <measurement group_id="B5" value="50.6" spread="9.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="69"/>
                    <measurement group_id="B5" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Complete Early Viral Response Below the Limit of Quantification (cEVR-LOQ)</title>
        <description>cEVR-LOQ was defined as serum HCV RNA below the limit of quantification (&lt; LOQ; i.e., 25 IU/mL) after 12 weeks of treatment. Post-switch groups were assessed 12 weeks after the switch.</description>
        <time_frame>after 12 weeks of treatment</time_frame>
        <population>Full Analysis Set (FAS) For Efficacy, defined as all randomized participants who were randomized after the 2nd protocol amendment</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>ALV 600 mg QD with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>ALV 800 mg QD with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>ALV placebo with PEG and RBV for up to 48 weeks; participants not achieving cEVR could switch to active ALV.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>ALV 400 mg BID with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Treatment C1A</title>
            <description>ALV 600 mg QD with PEG and RBV in participants not achieving cEVR in Treatment C subset C1.</description>
          </group>
          <group group_id="O6">
            <title>Treatment C2A</title>
            <description>ALV 400 mg BID with PEG and RBV in participants not achieving cEVR in Treatment C subset C2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete Early Viral Response Below the Limit of Quantification (cEVR-LOQ)</title>
          <description>cEVR-LOQ was defined as serum HCV RNA below the limit of quantification (&lt; LOQ; i.e., 25 IU/mL) after 12 weeks of treatment. Post-switch groups were assessed 12 weeks after the switch.</description>
          <population>Full Analysis Set (FAS) For Efficacy, defined as all randomized participants who were randomized after the 2nd protocol amendment</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="109"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2"/>
                    <measurement group_id="O2" value="61.1"/>
                    <measurement group_id="O3" value="35.5"/>
                    <measurement group_id="O4" value="74.3"/>
                    <measurement group_id="O5" value="45.5"/>
                    <measurement group_id="O6" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Complete Early Viral Response Below the Limit of Detection (cEVR-LOD)</title>
        <description>cEVR-LOD was defined as serum HCV RNA below the limit of detection (&lt; LOD; i.e., 10 IU/mL) after 12 weeks of treatment. Post-switch groups were assessed 12 weeks after the switch.</description>
        <time_frame>after 12 weeks of treatment</time_frame>
        <population>FAS For Efficacy</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>ALV 600 mg QD with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>ALV 800 mg QD with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>ALV placebo with PEG and RBV for up to 48 weeks; participants not achieving cEVR could switch to active ALV.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>ALV 400 mg BID with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Treatment C1A</title>
            <description>ALV 600 mg QD with PEG and RBV in participants not achieving cEVR in Treatment C subset C1.</description>
          </group>
          <group group_id="O6">
            <title>Treatment C2A</title>
            <description>ALV 400 mg BID with PEG and RBV in participants not achieving cEVR in Treatment C subset C2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete Early Viral Response Below the Limit of Detection (cEVR-LOD)</title>
          <description>cEVR-LOD was defined as serum HCV RNA below the limit of detection (&lt; LOD; i.e., 10 IU/mL) after 12 weeks of treatment. Post-switch groups were assessed 12 weeks after the switch.</description>
          <population>FAS For Efficacy</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="109"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1"/>
                    <measurement group_id="O2" value="41.7"/>
                    <measurement group_id="O3" value="20.9"/>
                    <measurement group_id="O4" value="58.7"/>
                    <measurement group_id="O5" value="39.4"/>
                    <measurement group_id="O6" value="73.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Sustained Viral Response 12 Weeks After Treatment (SVR12)-LOQ and SVR12-LOD</title>
        <description>SVR12-LOQ and SVR12-LOD were defined as serum HCV RNA &lt; LOQ and serum HCV RNA &lt; LOD 12 weeks after treatment, respectively.</description>
        <time_frame>12 weeks after treatment</time_frame>
        <population>FAS For Efficacy</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>ALV 600 mg QD with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>ALV 800 mg QD with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>ALV placebo with PEG and RBV for up to 48 weeks; participants not achieving cEVR could switch to active ALV.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>ALV 400 mg BID with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Treatment C1A</title>
            <description>ALV 600 mg QD with PEG and RBV in participants not achieving cEVR in Treatment C subset C1.</description>
          </group>
          <group group_id="O6">
            <title>Treatment C2A</title>
            <description>ALV 400 mg BID with PEG and RBV in participants not achieving cEVR in Treatment C subset C2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Sustained Viral Response 12 Weeks After Treatment (SVR12)-LOQ and SVR12-LOD</title>
          <description>SVR12-LOQ and SVR12-LOD were defined as serum HCV RNA &lt; LOQ and serum HCV RNA &lt; LOD 12 weeks after treatment, respectively.</description>
          <population>FAS For Efficacy</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="109"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR12-LOQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.7"/>
                    <measurement group_id="O2" value="51.9"/>
                    <measurement group_id="O3" value="14.5"/>
                    <measurement group_id="O4" value="65.1"/>
                    <measurement group_id="O5" value="18.2"/>
                    <measurement group_id="O6" value="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR12-LOD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.9"/>
                    <measurement group_id="O2" value="50.9"/>
                    <measurement group_id="O3" value="14.5"/>
                    <measurement group_id="O4" value="63.3"/>
                    <measurement group_id="O5" value="18.2"/>
                    <measurement group_id="O6" value="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Sustained Viral Response 24 Weeks After Treatment (SVR24)-LOQ and SVR24-LOD</title>
        <description>SVR24-LOQ and SVR24-LOD were defined as serum HCV RNA &lt; LOQ and serum HCV RNA &lt; LOD 24 weeks after treatment, respectively.</description>
        <time_frame>24 weeks after treatment</time_frame>
        <population>FAS For Efficacy</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>ALV 600 mg QD with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>ALV 800 mg QD with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>ALV placebo with PEG and RBV for up to 48 weeks; participants not achieving cEVR could switch to active ALV.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>ALV 400 mg BID with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Treatment C1A</title>
            <description>ALV 600 mg QD with PEG and RBV in participants not achieving cEVR in Treatment C subset C1.</description>
          </group>
          <group group_id="O6">
            <title>Treatment C2A</title>
            <description>ALV 400 mg BID with PEG and RBV in participants not achieving cEVR in Treatment C subset C2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Sustained Viral Response 24 Weeks After Treatment (SVR24)-LOQ and SVR24-LOD</title>
          <description>SVR24-LOQ and SVR24-LOD were defined as serum HCV RNA &lt; LOQ and serum HCV RNA &lt; LOD 24 weeks after treatment, respectively.</description>
          <population>FAS For Efficacy</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="109"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVR24-LOQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.8"/>
                    <measurement group_id="O2" value="51.9"/>
                    <measurement group_id="O3" value="14.5"/>
                    <measurement group_id="O4" value="65.1"/>
                    <measurement group_id="O5" value="18.2"/>
                    <measurement group_id="O6" value="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVR24-LOD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="14.5"/>
                    <measurement group_id="O4" value="63.3"/>
                    <measurement group_id="O5" value="18.2"/>
                    <measurement group_id="O6" value="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Rapid Viral Response (RVR)-LOQ and RVR-LOD</title>
        <description>RVR-LOQ and RVR-LOD were defined as serum HCV RNA &lt; LOQ and serum HCV RNA &lt; LOD after 4 weeks of treatment, respectively. Post-switch groups were assessed 4 weeks after the switch.</description>
        <time_frame>after 4 weeks of treatment</time_frame>
        <population>FAS For Efficacy</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>ALV 600 mg QD with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>ALV 800 mg QD with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>ALV placebo with PEG and RBV for up to 48 weeks; participants not achieving cEVR could switch to active ALV.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>ALV 400 mg BID with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Treatment C1A</title>
            <description>ALV 600 mg QD with PEG and RBV in participants not achieving cEVR in Treatment C subset C1.</description>
          </group>
          <group group_id="O6">
            <title>Treatment C2A</title>
            <description>ALV 400 mg BID with PEG and RBV in participants not achieving cEVR in Treatment C subset C2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Rapid Viral Response (RVR)-LOQ and RVR-LOD</title>
          <description>RVR-LOQ and RVR-LOD were defined as serum HCV RNA &lt; LOQ and serum HCV RNA &lt; LOD after 4 weeks of treatment, respectively. Post-switch groups were assessed 4 weeks after the switch.</description>
          <population>FAS For Efficacy</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="109"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RVR-LOQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="7.3"/>
                    <measurement group_id="O4" value="41.3"/>
                    <measurement group_id="O5" value="39.4"/>
                    <measurement group_id="O6" value="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RVR-LOD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1"/>
                    <measurement group_id="O2" value="8.3"/>
                    <measurement group_id="O3" value="2.7"/>
                    <measurement group_id="O4" value="22.9"/>
                    <measurement group_id="O5" value="18.2"/>
                    <measurement group_id="O6" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Partial Early Virologic Response After 12 Weeks of Treatment (pEVR)-LOQ and pEVR-LOD</title>
        <description>pEVR-LOQ and pEVR-LOD were defined as a ≥ 2 log10 decrease in HCV RNA and still detectable (≥ LOQ and ≥ LOD, respectively) after 12 weeks of treatment. Post-switch groups were assessed 12 weeks after the switch.</description>
        <time_frame>after 12 weeks of treatment</time_frame>
        <population>FAS For Efficacy</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>ALV 600 mg QD with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>ALV 800 mg QD with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>ALV placebo with PEG and RBV for up to 48 weeks; participants not achieving cEVR could switch to active ALV.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>ALV 400 mg BID with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Treatment C1A</title>
            <description>ALV 600 mg QD with PEG and RBV in participants not achieving cEVR in Treatment C subset C1.</description>
          </group>
          <group group_id="O6">
            <title>Treatment C2A</title>
            <description>ALV 400 mg BID with PEG and RBV in participants not achieving cEVR in Treatment C subset C2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Partial Early Virologic Response After 12 Weeks of Treatment (pEVR)-LOQ and pEVR-LOD</title>
          <description>pEVR-LOQ and pEVR-LOD were defined as a ≥ 2 log10 decrease in HCV RNA and still detectable (≥ LOQ and ≥ LOD, respectively) after 12 weeks of treatment. Post-switch groups were assessed 12 weeks after the switch.</description>
          <population>FAS For Efficacy</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="109"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>pEVR-LOQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2"/>
                    <measurement group_id="O2" value="28.7"/>
                    <measurement group_id="O3" value="31.8"/>
                    <measurement group_id="O4" value="11.9"/>
                    <measurement group_id="O5" value="3.0"/>
                    <measurement group_id="O6" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pEVR-LOD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.3"/>
                    <measurement group_id="O2" value="48.1"/>
                    <measurement group_id="O3" value="46.4"/>
                    <measurement group_id="O4" value="27.5"/>
                    <measurement group_id="O5" value="9.1"/>
                    <measurement group_id="O6" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With End of Treatment Response (ETR)-LOQ and ETR-LOD</title>
        <description>ETR-LOQ and ETR-LOD were defined as serum HCV RNA &lt; LOQ and serum HCV RNA &lt; LOD at treatment end (completed or prematurely discontinued), respectively.</description>
        <time_frame>within 48 weeks</time_frame>
        <population>FAS For Efficacy</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>ALV 600 mg QD with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>ALV 800 mg QD with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>ALV placebo with PEG and RBV for up to 48 weeks; participants not achieving cEVR could switch to active ALV.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>ALV 400 mg BID with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Treatment C1A</title>
            <description>ALV 600 mg QD with PEG and RBV in participants not achieving cEVR in Treatment C subset C1.</description>
          </group>
          <group group_id="O6">
            <title>Treatment C2A</title>
            <description>ALV 400 mg BID with PEG and RBV in participants not achieving cEVR in Treatment C subset C2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With End of Treatment Response (ETR)-LOQ and ETR-LOD</title>
          <description>ETR-LOQ and ETR-LOD were defined as serum HCV RNA &lt; LOQ and serum HCV RNA &lt; LOD at treatment end (completed or prematurely discontinued), respectively.</description>
          <population>FAS For Efficacy</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="109"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ETR-LOQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.2"/>
                    <measurement group_id="O2" value="74.1"/>
                    <measurement group_id="O3" value="33.6"/>
                    <measurement group_id="O4" value="82.6"/>
                    <measurement group_id="O5" value="51.5"/>
                    <measurement group_id="O6" value="73.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ETR-LOD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.8"/>
                    <measurement group_id="O2" value="70.4"/>
                    <measurement group_id="O3" value="31.8"/>
                    <measurement group_id="O4" value="78.9"/>
                    <measurement group_id="O5" value="36.4"/>
                    <measurement group_id="O6" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Abnormal Alanine Aminotransferase (ALT) at Baseline Who Had Normalized ALT at Treatment End and Study End</title>
        <time_frame>Up to 48 weeks</time_frame>
        <population>Participants in the FAS For Efficacy with abnormal ALT at baseline and available data at the respective time point</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>ALV 600 mg QD with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>ALV 800 mg QD with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>ALV placebo with PEG and RBV for up to 48 weeks; participants not achieving cEVR could switch to active ALV.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>ALV 400 mg BID with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Treatment C1A</title>
            <description>ALV 600 mg QD with PEG and RBV in participants not achieving cEVR in Treatment C subset C1.</description>
          </group>
          <group group_id="O6">
            <title>Treatment C2A</title>
            <description>ALV 400 mg BID with PEG and RBV in participants not achieving cEVR in Treatment C subset C2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Abnormal Alanine Aminotransferase (ALT) at Baseline Who Had Normalized ALT at Treatment End and Study End</title>
          <population>Participants in the FAS For Efficacy with abnormal ALT at baseline and available data at the respective time point</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="61"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="14"/>
                <count group_id="O6" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>End of Treatment (n = 53,49,60,53,14,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.4"/>
                    <measurement group_id="O2" value="77.6"/>
                    <measurement group_id="O3" value="59.0"/>
                    <measurement group_id="O4" value="83.0"/>
                    <measurement group_id="O5" value="35.7"/>
                    <measurement group_id="O6" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study (n = 49,42,18,46,13,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.7"/>
                    <measurement group_id="O2" value="61.2"/>
                    <measurement group_id="O3" value="18.0"/>
                    <measurement group_id="O4" value="67.9"/>
                    <measurement group_id="O5" value="21.4"/>
                    <measurement group_id="O6" value="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With On-treatment Viral Breakthrough</title>
        <description>On-treatment viral breakthrough was defined as either:
Confirmed increase of HCV RNA ≥1 log10 above nadir (nadir = lowest HCV RNA value during treatment), or
HCV RNA becoming ≥ 100 IU/mL after previously being undetectable (&lt; LOQ) during treatment</description>
        <time_frame>within 48 weeks</time_frame>
        <population>FAS For Efficacy</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>ALV 600 mg QD with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>ALV 800 mg QD with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>ALV placebo with PEG and RBV for up to 48 weeks; participants not achieving cEVR could switch to active ALV.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>ALV 400 mg BID with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Treatment C1A</title>
            <description>ALV 600 mg QD with PEG and RBV in participants not achieving cEVR in Treatment C subset C1.</description>
          </group>
          <group group_id="O6">
            <title>Treatment C2A</title>
            <description>ALV 400 mg BID with PEG and RBV in participants not achieving cEVR in Treatment C subset C2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With On-treatment Viral Breakthrough</title>
          <description>On-treatment viral breakthrough was defined as either:
Confirmed increase of HCV RNA ≥1 log10 above nadir (nadir = lowest HCV RNA value during treatment), or
HCV RNA becoming ≥ 100 IU/mL after previously being undetectable (&lt; LOQ) during treatment</description>
          <population>FAS For Efficacy</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="109"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7"/>
                    <measurement group_id="O2" value="9.3"/>
                    <measurement group_id="O3" value="5.5"/>
                    <measurement group_id="O4" value="2.8"/>
                    <measurement group_id="O5" value="6.1"/>
                    <measurement group_id="O6" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Viral Relapse</title>
        <description>Viral relapse was defined as reappearance of detectable HCV RNA after previously being undetectable (&lt; LOQ) during treatment.</description>
        <time_frame>within 24 weeks after treatment</time_frame>
        <population>FAS For Efficacy</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment A</title>
            <description>ALV 600 mg QD with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Treatment B</title>
            <description>ALV 800 mg QD with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Treatment C</title>
            <description>ALV placebo with PEG and RBV for up to 48 weeks; participants not achieving cEVR could switch to active ALV.</description>
          </group>
          <group group_id="O4">
            <title>Treatment D</title>
            <description>ALV 400 mg BID with PEG and RBV for up to 48 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Treatment C1A</title>
            <description>ALV 600 mg QD with PEG and RBV in participants not achieving cEVR in Treatment C subset C1.</description>
          </group>
          <group group_id="O6">
            <title>Treatment C2A</title>
            <description>ALV 400 mg BID with PEG and RBV in participants not achieving cEVR in Treatment C subset C2.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Viral Relapse</title>
          <description>Viral relapse was defined as reappearance of detectable HCV RNA after previously being undetectable (&lt; LOQ) during treatment.</description>
          <population>FAS For Efficacy</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="109"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1"/>
                    <measurement group_id="O2" value="18.5"/>
                    <measurement group_id="O3" value="17.3"/>
                    <measurement group_id="O4" value="12.8"/>
                    <measurement group_id="O5" value="30.3"/>
                    <measurement group_id="O6" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Treatment A: On-treatment AEs</title>
          <description>Adverse events (AEs) occurring while on treatment in participants receiving ALV 600 mg QD with PEG and RBV for up to 48 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Treatment B: On-treatment AEs</title>
          <description>AEs occurring while on treatment in participants receiving ALV 800 mg QD with PEG and RBV for up to 48 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Treatment C1: On-treatment AEs</title>
          <description>AEs occurring while on treatment in participants receiving ALV placebo (and may have received ALV 600 mg QD post-switch) with PEG and RBV for up to 48 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Treatment C2: On-treatment AEs</title>
          <description>AEs occurring while on treatment in participants receiving ALV placebo (and may have received ALV 400 mg BID post-switch) with PEG and RBV for up to 48 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Treatment D: On-treatment AEs</title>
          <description>AEs occurring while on treatment in participants receiving ALV 400 mg BID with PEG and RBV for up to 48 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Treatment A: Post-treatment AEs</title>
          <description>AEs occurring after end of treatment in participants receiving ALV 600 mg QD with PEG and RBV for up to 48 weeks.</description>
        </group>
        <group group_id="E7">
          <title>Treatment B: Post-treatment AEs</title>
          <description>AEs occurring after end of treatment in participants receiving ALV 800 mg QD with PEG and RBV for up to 48 weeks.</description>
        </group>
        <group group_id="E8">
          <title>Treatment C1: Post-treatment AEs</title>
          <description>AEs occurring while on treatment in participants receiving ALV placebo (and may have received ALV 600 mg QD post-switch) with PEG and RBV for up to 48 weeks.</description>
        </group>
        <group group_id="E9">
          <title>Treatment C2: Post-treatment AEs</title>
          <description>AEs occurring while on treatment in participants receiving ALV placebo (and may have received ALV 400 mg BID post-switch) with PEG and RBV for up to 48 weeks.</description>
        </group>
        <group group_id="E10">
          <title>Treatment D: Post-treatment AEs</title>
          <description>AEs occurring after end of treatment in participants receiving ALV 400 mg BID with PEG and RBV for up to 48 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypopituitarism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Drug interaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Arthritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Salpingitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperamylasaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Hyperlipasaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage I</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="116" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="108" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="106" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="19" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="51" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="46" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Ocular icterus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Aphthous stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="51" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="45" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="36" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Total bile acids increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Suspiciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="19" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="28" subjects_at_risk="108"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="108"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>In April 2012, ALV and placebo were discontinued in all participants. Participants remained on PEG and RBV treatment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Vice President Clinical Research &amp; Development</name_or_title>
      <organization>Debiopharm International S.A.</organization>
      <phone>4121 321 01 11</phone>
      <email>info-international@debiopharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

